全文获取类型
收费全文 | 10950篇 |
免费 | 614篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 100篇 |
儿科学 | 279篇 |
妇产科学 | 151篇 |
基础医学 | 1630篇 |
口腔科学 | 269篇 |
临床医学 | 1050篇 |
内科学 | 2228篇 |
皮肤病学 | 255篇 |
神经病学 | 1143篇 |
特种医学 | 624篇 |
外科学 | 1493篇 |
综合类 | 60篇 |
一般理论 | 2篇 |
预防医学 | 597篇 |
眼科学 | 157篇 |
药学 | 751篇 |
中国医学 | 18篇 |
肿瘤学 | 807篇 |
出版年
2023年 | 47篇 |
2022年 | 102篇 |
2021年 | 199篇 |
2020年 | 131篇 |
2019年 | 185篇 |
2018年 | 249篇 |
2017年 | 169篇 |
2016年 | 265篇 |
2015年 | 315篇 |
2014年 | 399篇 |
2013年 | 464篇 |
2012年 | 740篇 |
2011年 | 727篇 |
2010年 | 461篇 |
2009年 | 475篇 |
2008年 | 669篇 |
2007年 | 696篇 |
2006年 | 749篇 |
2005年 | 724篇 |
2004年 | 686篇 |
2003年 | 647篇 |
2002年 | 573篇 |
2001年 | 150篇 |
2000年 | 125篇 |
1999年 | 115篇 |
1998年 | 156篇 |
1997年 | 99篇 |
1996年 | 75篇 |
1995年 | 73篇 |
1994年 | 78篇 |
1993年 | 57篇 |
1992年 | 62篇 |
1991年 | 48篇 |
1990年 | 47篇 |
1989年 | 43篇 |
1988年 | 42篇 |
1987年 | 43篇 |
1986年 | 29篇 |
1985年 | 31篇 |
1984年 | 41篇 |
1983年 | 41篇 |
1982年 | 27篇 |
1981年 | 17篇 |
1980年 | 28篇 |
1979年 | 20篇 |
1978年 | 29篇 |
1976年 | 26篇 |
1954年 | 24篇 |
1938年 | 17篇 |
1932年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
SSIEM 33rd Annual Symposium Cardiff, 10th–13th September 1996 Abstracts
Oral presentations 相似文献62.
Purpose
We reexamined the relationship between preoperative serum prostate specific antigen (PSA) and prostate cancer volume in 290 patients who underwent radical prostatectomy.Materials and Methods
Serum samples from 290 consecutive patients were remeasured with the automated monoclonal-monoclonal Tosoh AIA-600 assay. These values were correlated with individual cancer volume by measuring Pearson correlation coefficients (r).Results
Cancer was noted in the transition zone in 31 patients and in the peripheral zone in 259. Of the peripheral zone cancers 133 (51.4 percent) were organ confined and 126 (48.6 percent) were nonorgan confined, including 12 (9.5 percent) with histologically confirmed lymph node metastasis (stage D1). The 259 peripheral zone cancers had a correlation coefficient with PSA (r = 0.499, p less than 0.0001). After distributing the 259 cases into cancer volume groups we found a large overlap in mean preoperative serum PSA, including 65 with 50 percent or greater Gleason grade 4 or 5 disease (r = 0.508). The correlation coefficients of cancer volume with PSA in 133 organ confined cancers, 114 nonorgan confined cancers without lymph node metastases and 12 nonorgan confined cancers with positive lymph nodes were 0.382, 0.438 and 0.363, respectively. The 31 transition zone cancers showed a correlation coefficient with PSA (r = 0.81). After excluding 2 cases with extreme PSA and cancer volume the correlation coefficient decreased (r = 0.077).Conclusions
Even when remeasured with an automated monoclonal-monoclonal assay serum PSA alone is unable to predict preoperatively cancer volume or distinguish between organ and nonorgan confined cancer in peripheral and transition zone tumors of the prostate. 相似文献63.
From the flowers of ARNICA CHAMISSONIS L ESS, sub-sp. FOLIOSA (N UTT.) M AGUIRE and its variety INCANA (G RAY) H ULTEN two new naturally occuring pseudoguaianolides were isolated and their structures established by spectroscopic methods. They are shown to be 4-O-acetyl-6-desoxychamissonolide ( 3) and the propionylic ester of 11,13-dihydrohelenalin which was named arnicolide G ( 6). 相似文献
64.
Thomas Lehrnbecher Andreas Trusen Frank Deinlein Burkhard Hcht Alexander Marx Joachim Kühl 《Pediatric blood & cancer》2003,40(1):13-17
Lymphoproliferative disorder (LPD) is described in only a few children receiving chemotherapy for cancer. In all of them, an association between LPD and EBV (Epstein‐Barr Virus) was found. We report on a patient who developed LPD not associated with EBV while receiving chemotherapy for relapsed acute lymphoblastic leukemia (ALL). Despite discontinuation of chemotherapy, administration of intravenous immunoglobulins and surgery the patient died. Growing experience with this disorder may allow better treatment options in the future and will show whether LPD not associated with EBV requires different therapeutic strategies. Med Pediatr Oncol 2003;40:13–17, © 2003 Wiley‐Liss, Inc. 相似文献
65.
Michael G Kiehl Ludwig Kraut Rainer Schwerdtfeger Bernd Hertenstein Mats Remberger Nicolaus Kroeger Mathias Stelljes Martin Bornhaeuser Hans Martin Christoph Scheid Arnold Ganser Axel R Zander Joachim Kienast Gerhard Ehninger Dieter Hoelzer Volker Diehl Axel A Fauser Olle Ringden 《Journal of clinical oncology》2004,22(14):2816-2825
PURPOSE: The role of unrelated allogeneic stem-cell transplantation in acute lymphoblastic leukemia (ALL) patients is still not clear, and only limited data are available from the literature. We analyzed factors affecting clinical outcome of ALL patients receiving a related or unrelated stem-cell graft from matched donors. PATIENTS AND METHODS: The total study population was 264 adult patients receiving a myeloablative allogeneic stem-cell transplant for ALL at nine bone marrow transplantation centers between 1990 and 2002. Of these, 221 patients receiving a matched related or unrelated graft were analyzed. One hundred forty-eight patients received transplantation in complete remission; 62 patients were in relapse; and 11 patients were refractory to chemotherapy before transplant. Fifty percent of patients received bone marrow, and 50% received peripheral blood stem cell from a human leukocyte antigen-identical related (n = 103), or matched unrelated (n = 118) donor. RESULTS: Disease-free survival (DFS) at 5 years was 28%, with 76 patients (34%) still alive (2.2 to 103 months post-transplantation), and 145 deceased (65 relapses, transplant-related mortality, 45%). We observed an advantage regarding DFS in favor of patients receiving transplantation during their first complete remission (CR) in comparison with patients receiving transplantation in or after second CR (P =.014) or who relapsed (P <.001). We observed a clear trend toward improved survival in favor of B-lineage ALL patients compared with T-lineage ALL patients (P =.052), and Philadelphia chromosome-positive patients had no poorer outcome than Philadelphia chromosome-negative patients. Total-body irradiation-based conditioning improved DFS in comparison with busulfan (P =.041). CONCLUSION: Myeloablative matched related or matched unrelated allogeneic hematopoietic stem-cell transplantation in ALL patients should be performed in first CR. 相似文献
66.
Udo Vanhoefer Mitra Tewes Federico Rojo Olaf Dirsch Norbert Schleucher Oliver Rosen Joachim Tillner Andreas Kovar Ada H Braun Tanja Trarbach Siegfried Seeber Andreas Harstrick José Baselga 《Journal of clinical oncology》2004,22(1):175-184
PURPOSE: To investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with solid tumors that express epidermal growth factor receptor (EGFR). PATIENTS AND METHODS: This was a phase I dose-escalation trial of EMD72000 in patients with advanced, EGFR-positive, solid malignancies that were not amenable to any established chemotherapy or radiotherapy treatment. EMD72000 was administered weekly without routine premedication until disease progression or unacceptable toxicity. RESULTS: Twenty-two patients were treated with EMD72000 at five different dose levels (400 to 2,000 mg/wk). National Cancer Institute common toxicity criteria grade 3 headache and fever occurring after the first infusion were dose limiting at 2,000 mg/wk; thus, the maximum-tolerated dose was 1,600 mg/wk. No other severe side effects, especially no allergic reactions or diarrhea, were observed. Acneiform skin reaction was the most common toxicity, but it was mild, with grade 1 in 11 patients (50%) and grade 2 in three patients (14%). Pharmacokinetic analyses demonstrated a predictable pharmacokinetic profile for EMD72000. Pharmacodynamic studies on serial skin biopsies revealed that EMD72000 effectively abrogated EGFR-mediated cell signaling (eg, reduced phosphorylation of EGFR and mitogen-activated protein kinase), with no alteration in total EGFR protein. Objective responses (23%; 95% CI, 8% to 45%) and disease stabilization (27%; 95% CI, 11% to 50%) were achieved at all dose levels, and responding patients received treatment for up to 18 months without cumulative toxicity. CONCLUSION: Treatment with EMD72000 was well tolerated and showed evidence of activity in heavily pretreated patients with EGFR-expressing tumors. EMD72000 at the investigated doses significantly inhibited downstream EGFR-dependent processes. 相似文献
67.
68.
69.
G. Hempel Sebastian Krümpelmann Antje May-Manke Barbara Hohenlöchter Gottfried Blaschke Heribert Jürgens Joachim Boos 《Cancer chemotherapy and pharmacology》1997,40(1):45-50
To contribute to effective and safe outpatient treatment, we investigated the metabolism of trofosfamide (Trofo) after oral
administration. We analyzed Trofo metabolism in 15 patients aged from 3 to 73 years who were treated with 150 or 250 mg/m2 Trofo in combination with etoposide. Serum samples were collected with 13 patients after oral administration, and Trofo and
its dechloroethylated metabolites were quantified by gas chromatography. Urine samples were collected from five patients and
analyzed by same method. Ifosfamide (Ifo) was the main metabolite in serum and urine (AUCTrofo:AUCIfo 1:13), whereas cyclophosphamide (Cyclo) was formed in smaller amounts (AUCIfo:AUCCyclo 18:1). Ifo and Cyclo were further oxidized in the chloroethyl side chains to form 2- and 3-dechloroethylifosfamide in varying
quantities. The urinary excretion of Trofo and its dechloroethylated metabolites amounted to about 10% of the total dose.
Our results confirm former in vitro observations about the metabolism of Trofo. The main side-chain metabolites Ifo and Cyclo
can be further activated by oxidation and formation of their respective phosphoramide mustards. Hence, Trofo is an interesting
agent for oral chemotherapy.
Received 21 July 1996 / Accepted: 11 November 1996 相似文献
70.